These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2897925)

  • 81. Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors.
    Vasse M; Chagraoui A; Protais P
    Eur J Pharmacol; 1988 Mar; 148(2):221-9. PubMed ID: 2897924
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.
    Carvey PM; Kao LC; Zhang TJ; Amdur RL; Lin DH; Singh R; Klawans HL
    Pharmacol Biochem Behav; 1990 Feb; 35(2):291-300. PubMed ID: 2320636
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol.
    Kamata K; Ogawa K; Noma S; Kameyama T
    J Pharmacobiodyn; 1986 Jan; 9(1):88-94. PubMed ID: 3712211
    [TBL] [Abstract][Full Text] [Related]  

  • 84. SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine.
    Mereu G; Collu M; Ongini E; Biggio G; Gessa GL
    Eur J Pharmacol; 1985 May; 111(3):393-6. PubMed ID: 3894035
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine.
    Boye SM; Rompré PP
    J Neurosci; 2000 Feb; 20(3):1229-39. PubMed ID: 10648727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Distinct effects of two stresses on the behavioral response to apomorphine.
    Csernansky JG; Csernansky CA; Hollister LE
    Life Sci; 1984 Oct; 35(14):1513-8. PubMed ID: 6541282
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat.
    Deutsch SI; Halperin R; Stanley M; Davis KL
    Neurochem Res; 1985 Apr; 10(4):491-8. PubMed ID: 2582289
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis.
    Morelli M; Longoni R; Spina L; Di Chiara G
    Psychopharmacology (Berl); 1986; 89(2):259-60. PubMed ID: 3088647
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.
    Cohen BM; Tsuneizumi T; Baldessarini RJ; Campbell A; Babb SM
    Psychopharmacology (Berl); 1992; 108(3):338-44. PubMed ID: 1355924
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor.
    Salamone J; Baskin P
    Pharmacol Biochem Behav; 1996 Jan; 53(1):179-83. PubMed ID: 8848448
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats.
    Suemaru K; Gomita Y; Furuno K; Araki Y
    Pharmacol Biochem Behav; 1993 Sep; 46(1):135-9. PubMed ID: 7902980
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Differential effects of dopamine agonists in mature and immature rats.
    McDevitt JT; Setler PE
    Eur J Pharmacol; 1981 Jun; 72(1):69-75. PubMed ID: 6973482
    [TBL] [Abstract][Full Text] [Related]  

  • 93. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
    Yarbrough GG; Faison EP; Antolik EK
    Neurosci Lett; 1982 Dec; 34(3):321-3. PubMed ID: 6819493
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and neuroleptics.
    Lassen JB
    Acta Pharmacol Toxicol (Copenh); 1979 Aug; 45(2):161-5. PubMed ID: 40391
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.
    Ohno Y; Ishida K; Ishibashi T; Ikeda K; Kato T; Nakamura M
    Gen Pharmacol; 1995 May; 26(3):489-94. PubMed ID: 7789721
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Apomorphine-induced alterations in cortical EEG activity of rats. Involvement of D-1 and D-2 dopamine receptors.
    Kropf W; Kuschinsky K; Krieglstein J
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Dec; 340(6 Pt 2):718-25. PubMed ID: 2699354
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics.
    Arnt J; Christensen AV
    Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cocaine-induced behavioral sensitization: effects of haloperidol and SCH 23390 treatments.
    Mattingly BA; Rowlett JK; Ellison T; Rase K
    Pharmacol Biochem Behav; 1996 Mar; 53(3):481-6. PubMed ID: 8866944
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
    Gattaz WF; Emrich A; Behrens S
    J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Behavioral supersensitivity to apomorphine following chronic narcotic treatment in the guinea pig.
    Carlson KR; Almasi J
    Psychopharmacology (Berl); 1978 May; 57(3):273-7. PubMed ID: 97708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.